13th edition

Format
HYBRID

December 3rd & 4th, 2024

IN-PERSON | LILLE, FR

December 11th& 12th 2024

ONLINE MEETINGS

Valentine Delabie

The BioFIT 2021 brochure is available!

The BioFIT 2021 brochure is available!

Discover the BioFIT 2021 brand new brochure!

Download it to learn more about the 10th edition of BioFIT, the leading European partnering event for early-stage deals and investment rounds in the Life Sciences field!

Sponsors

Contact

Juliette Vanbastelaere

The BioFIT 2021 brochure is available! Read More »

Save the Date for BioFIT 2021

Save the Date for BioFIT 2021

A successful 2020 edition

For this 9th edition, BioFIT, the leading European partnering event for early-stage deals and investment rounds in the Life Sciences field, was organised for the first time in a digital format and was a real success.

This digital experience over 4 days has allowed participants to take away new ideas, new collaborations and new funding opportunities from their participation, all to build the innovations of tomorrow in the Life Science industry.

Over 1,000 attendees from over 36 countries have attended BioFIT/MedFIT Digital 2020. During the 4 day-event, 9,000 one-to-one meetings have been generated, 70 speakers have debated the right funding sources for early-stage innovation, the best practices in academia-industry R&D collaborations, and the winning ways to nurture emerging assets, 70 entities have increased their visibility through exhibition virtual stands, and 62 innovative projects previously selected have had the opportunity to pitch.

Save the date for the 10th edition

We hope to get the pleasure to welcome you to the next edition of BioFIT, in the charming city of Strasbourg, on December 14th and 15th, 2021. Looking forward to seeing you!

Register now and benefit from the Super Early Bird offer valid until March 31st, 2021!

Sponsors

Contact

Juliette Vanbastelaere

Save the Date for BioFIT 2021 Read More »

And the winners of the BioFIT 2020 Pitch Sessions are…

And the winners of the BioFIT 2020 Pitch Sessions are…

StemSight, elected as the most innovative start-up

Among 35 applications received, 13 start-ups were selected to pitch during the Start-up Slams at BioFIT in different categories such as oncology, ophthalmology, cell therapy, infection, parasitic, inflammation, cardio-metabolic, gastrointestinal and tools (research, delivery, clinical development). StemSight, a Finnish start-up involved in Ophthalmology and Cell Therapy, represented by Laura Koivusalo, Founder and CEO, is the winner of this year’s edition of the Start-up Slams:

We are honoured to be considered as the most innovative start-up by the high-level jury of BioFIT, even though we are still in the very early stages. It is especially valuable to gain feedback on not just the pitching but also on the technology and business considerations of the project. This recognition from the BioFIT jury will hopefully also give an additionally boost to our fundraising.”

StemSight is developing new treatments for blindness by differentiating cell therapies from human pluripotent stem cells. StemSight is initially targeting a rare form of corneal blindness called limbal stem cell deficiency, a state where the cells responsible for the normal healing of the ocular surface are lost to injury or disease. StemSight’s approach aims to cure limbal stem cell deficiency permanently, by implanting allogeneic pluripotent stem cell-derived limbal stem cells to the corneal surface. StemSight is currently in the process of spinning out from Tampere University in Finland and raising their seed funding.

Antikor Biopharma Ltd., elected as the most promising technology

20 TTOs, universities, research institutes and companies applied to the BioFIT Collaborative and Licensing Opportunity Presentations to showcase their technology in front of potential partners in order to entail a collaborative project and / or a licensing deal. 8 of them have been selected to pitch during BioFIT in 3 different categories: infection/parasitic, oncology, tools/diagnostic. Antikor Biopharma Ltd., a British project involved in Oncology, represented by Dr. Mahendra Deonarain, Chief Executive and Science Officer, received the “Most Promising Technology” award:

This was our first attendance at BioFIT and were impressed by the organisation and breadth of attendees. We were pleased to have been selected to give a partnering presentation and even more honoured to be selected as a winner for the best technology pitch. The judges feedback was very detailed and knowledgeable and their understanding of our value proposition and choice for the award validates our approach. We are indeed grateful for this recognition. Our progress in a difficult 2020 has been due to the exceptional team at Antikor and we hope that 2021 will be our most successful year yet.”

Antikor, based in Stevenage, UK are innovators in ADCs (Antibody-Drug Conjugates). After many years of disappointment and failures, the ADC area has recently resurged, doubling the number of product approvals in the last 2 years. However, despite this renewed optimism, treating difficult solid tumours like gastric, pancreatic and lung remain a significant challenge which is where Antikor’s Fragment Drug Conjugate (FDC) technology fits. FDCs uses smaller antibody formats, optimised for superior tumour penetration, but systemically clear more rapidly providing reduced normal tissue exposure. Using carefully chosen, stable human frameworks, highly tolerable to bioconjugation, Antikor’s FDCs obtain higher payload loading ratios making them more potent. These features leads to benefits of improved efficacy and superior tolerability leading to a larger therapeutic window for treating solid tumours. Antikor has a strong platform for FDC discovery, an integrated R&D team to develop innovative products, backed by strong IP. Antikor’s two lead programmes are at the advanced pre-clinical stage: ANT-43 (breast and gastric cancer) is partnered with Hong Kong-listed Pharma company, Essex Biotechnology and our new flagship programme, ANT-45 is for gastric, lung and colon cancer. Antikor attended BioFIT 2020 to introduce its technology and products and to initiate partnership discussions for ANT-45.

PRONOZIA, elected as the most innovative animal health project

3 innovative animal health projects have been selected among companies that applied to the Animal Health Presentations and showcased their project in front of potential partners and investors. PRONOZIA, a French project involved in Animal Health, represented by Olivier Denis, President and Founder, is the winner of this year’s edition of the Animal Health Presentations:

We are very proud that “ZAG concept by PRONOZIA” wins the 2020 award of the “most innovative animal health project” presented by SIMV/BioFIT. Winning this award in a highly competition line-up, it is a great recognition of huge work accomplished and a great satisfaction for PRONOZIA team and partners. “ZAG concept” is a new generation decision support tool at the service of vet professionals, based on data science and data management. Thanks to SIMV and BioFIT for organising these pitching sessions which are very interesting opportunities to share with investors and partners the outcome of 3 years of R&D work.”

PRONOZIA is a company specialised in digital technologies applied to the animal health field. PRONOZIA develop innovative custom digital tools and services for animal healthcare professional, based on data science and data management methodologies using a combination of algorithmic mathematics, statistical models and machine learning. PRONOZIA finalises the development of “ZAG concept”, a decision support platform. “ZAG concept” provides qualified scientific data for helping vet practitioners to improve management of their daily clinical cases.

Sponsors

Contact

Juliette Vanbastelaere

And the winners of the BioFIT 2020 Pitch Sessions are… Read More »

Three business strategy tips to help your company grow

Three business strategy tips to help your company grow

Are you part of a life sciences business looking to grow? Check out these three business strategy tips from @Turnstone Communications, the driving force behind our media partner @BioVox news!

Sponsors

Contact

Juliette Vanbastelaere

Three business strategy tips to help your company grow Read More »

Belgium: the number one biotech country in Europe!

Belgium: the number one biotech country in Europe!

2020 is the third year in a row that Belgium has ranked as the best biotech country in Europe!
To keep up to date on this fantastic life sciences ecosystem, follow our media partner @BioVox via their newsletter or on Twitter & LinkedIn!

Sponsors

Contact

Juliette Vanbastelaere

Belgium: the number one biotech country in Europe! Read More »

We are very honoured to count Sanofi among the Sponsors of BioFIT 2020

We are very honoured to count Sanofi among the Sponsors of BioFIT 2020

Many thanks to Sanofi for joining BioFIT 2020 as a Bronze Sponsor

Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people they serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare.

Join key BioFIT 2020 sponsors such as Pfizer, Boehringer Ingelheim, Sanofi, Roche, Novo Nordisk, MSD Animal Health, Evotec and MSD to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

For more information about the sponsorship opportunities, visit the dedicated site page.

Sponsors

Contact

Juliette Vanbastelaere

We are very honoured to count Sanofi among the Sponsors of BioFIT 2020 Read More »

We are very honoured to count Bayer among the Sponsors of BioFIT 2020

We are very honoured to count Bayer among the Sponsors of BioFIT 2020

Many thanks to Bayer for joining BioFIT 2020 as a Bronze Sponsor

Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With their innovative products, they are contributing to finding solutions to some of the major challenges of our time.

With life expectancy continuing to rise, they improve quality of life for a growing population by focusing their research and development activities on preventing, alleviating and treating diseases. They are also making an important contribution to providing a reliable supply of high-quality food, feed and plant-based raw materials.

Their goal is to create value for their customers, stockholders and employees, while also strengthening the company’s earning power. They are committed to operating sustainably and addressing their social and ethical responsibilities. Employees with a passion for innovation enjoy excellent development opportunities at Bayer. All this goes to make up their purpose: Science for a better life.

Join key BioFIT 2020 sponsors such as Pfizer, Boehringer Ingelheim, Bayer, Roche, Novo Nordisk, MSD Animal Health, Evotec and MSD to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

For more information about the sponsorship opportunities, visit the dedicated site page.

Sponsors

Contact

Juliette Vanbastelaere

We are very honoured to count Bayer among the Sponsors of BioFIT 2020 Read More »

We are very honoured to count Roche among the Sponsors of BioFIT 2020

We are very honoured to count Roche among the Sponsors of BioFIT 2020

Many thanks to Roche for joining BioFIT 2020 as a Bronze Sponsor

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to invest heavily in research and development with CHF 11 billion in 2018. Alongside the broad internal pipeline, external innovation has always been a critical component of the Roche research and development strategy.

Join key BioFIT 2020 sponsors such as Pfizer, Boehringer Ingelheim, Roche, Novo Nordisk, MSD Animal Health, Evotec and MSD to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

For more information about the sponsorship opportunities, visit the dedicated site page.

Sponsors

Contact

Juliette Vanbastelaere

We are very honoured to count Roche among the Sponsors of BioFIT 2020 Read More »

We are very honoured to count Boehringer Ingelheim among the Sponsors of BioFIT 2020

We are very honoured to count Boehringer Ingelheim among the Sponsors of BioFIT 2020

Many thanks to Boehringer Ingelheim for joining BioFIT 2020 as a Bronze Sponsor

Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies. 

Improving the health and quality of life of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention. 

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of 17.5 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 18.1 per cent of net sales. 

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment. 

Join key BioFIT 2020 sponsors such as Pfizer, Boehringer Ingelheim, Novo Nordisk, MSD Animal Health, Evotec and MSD to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

For more information about the sponsorship opportunities, visit the dedicated site page.

Sponsors

Contact

Juliette Vanbastelaere

We are very honoured to count Boehringer Ingelheim among the Sponsors of BioFIT 2020 Read More »

In-depth Interview with AND BioPharma, winner of the 2019 Animal Health Presentations

In-depth Interview with AND BioPharma, winner of the 2019 Animal Health Presentations

AND BioPharma, elected as the most Innovative Animal Health project of BioFIT 2019

3 innovative animal health projects have been selected among companies that applied to the Animal Health Collaborative Opportunity Presentations and showcased their project in front of potential partners and investors. AND BioPharma, a Belgium project represented by Peter Jens, CEO and Business Development, is the winner of this year’s edition of the Animal Health Collaborative Opportunity Presentations.

Please introduce yourself and ALCEDIAG. How your company is born?

Peter Jens: A.N.D. stands for As Nature Does. The patented broad biological principle of DNA self toxicity was the reason why we established the company. By applying random fragmented self DNA on the same organism one inhibits the growth of a population. We use this to develop novel anti-helminth, anti-invectives and skin anti-bacterials that -without side effects- are species specific and may balance healthy microbiomes. Our sister company AND Agri focusses itself on agricultural solutions. Our team is a very diverse mix of cultures, backgrounds and aptitudes, but all crazy about disruptive innovations.

Why did you apply to the Pitch Sessions? What was your expectations?

P. J.: At this phase of the company development we need outsiders looking in and ask hard questions. Especially outside the scientific and academic community. We learn from it and cn adapt. And even find partners to work with. We did not have high expectations as the first three years most people we met laughed at us: “DNA being toxic? Ridiculous!”, but now science is discovering that there is an enormous amount of environmental DNA in the air that we breathe, the water we drink and the soils we grow our food in. And researchers noticed that that environmental does not only signify something, it dóes something too!.

What did this victory as the Most Innovative Animal Health Project bring to you and to AND BioPharma?

P. J.: It brought us a few good interested parties from the animal health, but we could not yet explain exactly how we would produce those exDNA fragments in mass, fit for commercial livestock purposes. Now that we published our “chimeric patent’ application https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020167128&tab=PCTBIBLIO parties know how we can use all types of natural libraries to get DNA fragments onto the targets. What we learned is that many pharma applications are focused on time/kill and dosage/kill relations. As Nature Does works differently: It only pushes back pathogens back in their population size so that ecological mechanisms take over.

What’s next for AND BioPharma now?

P. J.: We are anxiously waiting for the third patent application to be published. For many it will be a shocker, but for some parties that followed us, it will be an “Aha erlebnis”. In a practical sense we hope to publish at BioFit our first evidence on how to stop the MRSA USA 300 strain infection by its own DNA (and some other news on natural libraries, of course. That is what the European industry is waiting for.

AND BioPharma stimulates, in collaboration with the pharmaceutical industry, healthcare providers, insurance companies and thoughtleaders, the natural balance between hosts and troublesome invaders in humans and other animals. By the development of efficient and effectual medicines based on the powerful and proven self DNA-inhibition principle, discovered and patented at Frederico II University, Napels, Italy.

More information: www.andbiopharma.com

Sponsors

Contact

Juliette Vanbastelaere

In-depth Interview with AND BioPharma, winner of the 2019 Animal Health Presentations Read More »

Scroll to Top
  • No products in the cart.